These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

266 related articles for article (PubMed ID: 28589395)

  • 21. Prostate magnetic resonance imaging findings in patients treated for testosterone deficiency while on active surveillance for low-risk prostate cancer.
    Hashimoto T; Rahul K; Takeda T; Benfante N; Mulhall JP; Hricak H; Eastham JA; Vargas HA
    Urol Oncol; 2016 Dec; 34(12):530.e9-530.e14. PubMed ID: 27665357
    [TBL] [Abstract][Full Text] [Related]  

  • 22. Testosterone Therapy and Prostate Cancer: Incorporating Low-Level Evidence into Practical Recommendations.
    Morales A; Siemens DR
    Urol Clin North Am; 2022 Nov; 49(4):573-582. PubMed ID: 36309414
    [TBL] [Abstract][Full Text] [Related]  

  • 23. Testosterone therapy in prostate cancer: is it still a controversy?
    Bart AS; Van Hoof A; Badre-Hume R; Selvarajah J; Robillard K; Albala DM
    Curr Opin Urol; 2022 Nov; 32(6):598-606. PubMed ID: 36081393
    [TBL] [Abstract][Full Text] [Related]  

  • 24. The role of testosterone replacement therapy following radical prostatectomy.
    Khera M; Lipshultz LI
    Urol Clin North Am; 2007 Nov; 34(4):549-53, vi. PubMed ID: 17983894
    [TBL] [Abstract][Full Text] [Related]  

  • 25. Prostate-specific antigen changes and prostate cancer in hypogonadal men treated with testosterone replacement therapy.
    Coward RM; Simhan J; Carson CC
    BJU Int; 2009 May; 103(9):1179-83. PubMed ID: 19154450
    [TBL] [Abstract][Full Text] [Related]  

  • 26. Testosterone, testosterone therapy and prostate cancer.
    Yassin A; AlRumaihi K; Alzubaidi R; Alkadhi S; Al Ansari A
    Aging Male; 2019 Dec; 22(4):219-227. PubMed ID: 30614347
    [TBL] [Abstract][Full Text] [Related]  

  • 27. Point: urologists should take an active role in the diagnosis and treatment of hypogonadism in the aging male.
    Heaton JP
    Can J Urol; 2002 Dec; 9(6):1677-80. PubMed ID: 12517308
    [TBL] [Abstract][Full Text] [Related]  

  • 28. Testosterone therapy for men at risk for or with history of prostate cancer.
    Morgentaler A
    Curr Treat Options Oncol; 2006 Sep; 7(5):363-9. PubMed ID: 16904053
    [TBL] [Abstract][Full Text] [Related]  

  • 29. A rational approach to androgen therapy for hypogonadal men with prostate cancer.
    Kaufman J
    Int J Impot Res; 2006; 18(1):26-31. PubMed ID: 16208401
    [TBL] [Abstract][Full Text] [Related]  

  • 30. Effects of 8-Year Treatment of Long-Acting Testosterone Undecanoate on Metabolic Parameters, Urinary Symptoms, Bone Mineral Density, and Sexual Function in Men With Late-Onset Hypogonadism.
    Permpongkosol S; Khupulsup K; Leelaphiwat S; Pavavattananusorn S; Thongpradit S; Petchthong T
    J Sex Med; 2016 Aug; 13(8):1199-211. PubMed ID: 27436076
    [TBL] [Abstract][Full Text] [Related]  

  • 31. Is there a protective role of testosterone against high-grade prostate cancer? Incidence and severity of prostate cancer in 553 patients who underwent prostate biopsy: a prospective data register.
    Yassin A; Salman M; Talib RA; Yassin DJ
    Aging Male; 2017 Jun; 20(2):125-133. PubMed ID: 28282997
    [TBL] [Abstract][Full Text] [Related]  

  • 32. Safety of androgen therapy in men with prostate cancer.
    Rajan P; Tharakan T; Chen R
    Best Pract Res Clin Endocrinol Metab; 2022 Sep; 36(5):101628. PubMed ID: 35248487
    [TBL] [Abstract][Full Text] [Related]  

  • 33. Testosterone replacement therapy in hypogonadal men at high risk for prostate cancer: results of 1 year of treatment in men with prostatic intraepithelial neoplasia.
    Rhoden EL; Morgentaler A
    J Urol; 2003 Dec; 170(6 Pt 1):2348-51. PubMed ID: 14634413
    [TBL] [Abstract][Full Text] [Related]  

  • 34. Testosterone treatment is not associated with increased risk of prostate cancer or worsening of lower urinary tract symptoms: prostate health outcomes in the Registry of Hypogonadism in Men.
    Debruyne FM; Behre HM; Roehrborn CG; Maggi M; Wu FC; Schröder FH; Jones TH; Porst H; Hackett G; Wheaton OA; Martin-Morales A; Meuleman E; Cunningham GR; Divan HA; Rosen RC;
    BJU Int; 2017 Feb; 119(2):216-224. PubMed ID: 27409523
    [TBL] [Abstract][Full Text] [Related]  

  • 35. Prevalence of prostate cancer among hypogonadal men with prostate-specific antigen levels of 4.0 ng/mL or less.
    Morgentaler A; Rhoden EL
    Urology; 2006 Dec; 68(6):1263-7. PubMed ID: 17169647
    [TBL] [Abstract][Full Text] [Related]  

  • 36. The effects of testosterone replacement therapy on the prostate: a clinical perspective.
    Miah S; Tharakan T; Gallagher KA; Shah TT; Winkler M; Jayasena CN; Ahmed HU; Minhas S
    F1000Res; 2019; 8():. PubMed ID: 30828436
    [TBL] [Abstract][Full Text] [Related]  

  • 37. Critical Update of the 2010 Endocrine Society Clinical Practice Guidelines for Male Hypogonadism: A Systematic Analysis.
    Seftel AD; Kathrins M; Niederberger C
    Mayo Clin Proc; 2015 Aug; 90(8):1104-15. PubMed ID: 26205546
    [TBL] [Abstract][Full Text] [Related]  

  • 38. A new era of testosterone and prostate cancer: from physiology to clinical implications.
    Khera M; Crawford D; Morales A; Salonia A; Morgentaler A
    Eur Urol; 2014 Jan; 65(1):115-23. PubMed ID: 24011426
    [TBL] [Abstract][Full Text] [Related]  

  • 39. Prevention of prostate cancer by androgens: experimental paradox or clinical reality.
    Algarté-Génin M; Cussenot O; Costa P
    Eur Urol; 2004 Sep; 46(3):285-94; discussion 294-5. PubMed ID: 15306098
    [TBL] [Abstract][Full Text] [Related]  

  • 40. To treat or not to treat with testosterone replacement therapy: a contemporary review of management of late-onset hypogonadism and critical issues related to prostate cancer.
    Kava BR
    Curr Urol Rep; 2014 Jul; 15(7):422. PubMed ID: 24832199
    [TBL] [Abstract][Full Text] [Related]  

    [Previous]   [Next]    [New Search]
    of 14.